# US 9,872,894 B2 · Immunogenic polypeptide cocktail for the treatment of medullary thyroid carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,894 B2
- Document ID: US9872894B2
- Status: Granted
- Kind: B2
- Application number: 15/436,525
- Filed: 2017-02-17
- Published: 2017-08-31
- Granted: 2018-01-23
- Earliest claimed: 2016-02-25
- Assignees: Timothy Andrew Erickson
- Applicants: Timothy Andrew Erickson
- Inventors: Timothy Andrew Erickson
- Web page: https://patentgrep.com/patent/US9872894B2

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are immunogenic compositions that include one or more polypeptides that, when administered to a subject with adjuvant, elicit an immune response against medullary thyroid cancer. Disclosed are methods of eliciting an immune response and/or treating cancer, such as medullary thyroid carcinoma or other thyroid carcinomas.

## Claims

### Claim 1

A method of treating a subject who has medullary thyroid cancer by administering to the subject an immunogenic composition, which comprises SEQ ID NO: 2 in a suitable carrier and/or adjuvant.

### Claim 2

A method of treating a subject who has medullary thyroid cancer by administering to the subject an immunogenic composition, which consists of SEQ ID NO: 2 and SEQ. ID NO: 28 in a suitable carrier and/or adjuvant.

### Claim 3 (depends on 1)

The method of claim 1, whereby SEQ ID NO: 2 may be truncated by 1, 2, 3, 4, 5, 6 or 7 amino acids at either the amino terminus or carboxy terminus.

### Claim 4 (depends on 2)

A method of claim 2, whereby either SEQ ID NO: 2 and/or SEQ. ID NO: 28 may be truncated by 1, 2, 3, 4, 5, 6 or 7 amino acids at either the amino terminus or carboxy terminus.

### Claim 5

A method of treating a subject who has medullary thyroid cancer by administering to the subject an immunogenic composition, which comprises cDNA or mRNA encoding SEQ. ID NO: 2.

### Claim 6

A method of treating a subject who has medullary thyroid cancer by administering to the subject an immunogenic composition, which consists of cDNA or mRNA encoding SEQ. ID NO: 2 and SEQ. ID NO: 28.